Literature DB >> 29963126

Antitumor mechanisms of bifidobacteria.

Hongyun Wei1, Linlin Chen2, Guanghui Lian2, Junwen Yang2, Fujun Li2, Yiyou Zou2, Fanggen Lu1, Yani Yin2.   

Abstract

Cancer remains one of the most common causes of mortality globally. Chemotherapy, one of the major treatment strategies for cancer, primarily functions by targeting the cancer cells and affecting them physiologically, but also affects normal cells, which is a major concern at present. Therefore, adverse effects of chemotherapy drugs, including myelosuppression and liver and kidney damage, are of concern. Now, microbial products have attracted attention in cancer treatment research. Notably, carcinogenesis is considered to be associated with microbial dysbiosis, particularly the positive antitumor effects of bifidobacteria. Although there remains a substantial amount to be understood about the regulation of bifidobacteria, bifidobacteria remain an attractive and novel source of cancer therapeutics. The present review focuses on introducing the latest information on the antitumor effects of bifidobacteria and to propose future strategies for using bifidobacteria in the development of cancer therapeutics.

Entities:  

Keywords:  antitumor; bifidobacteria; cancer

Year:  2018        PMID: 29963126      PMCID: PMC6019968          DOI: 10.3892/ol.2018.8692

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  80 in total

1.  Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats.

Authors:  Takayuki Sasaki; Minoru Fujimori; Yoshinori Hamaji; Yoshihisa Hama; Ken-Ichi Ito; Jun Amano; Shun'ichiro Taniguchi
Journal:  Cancer Sci       Date:  2006-07       Impact factor: 6.716

2.  Capability of the two microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children.

Authors:  Luca Mogna; Mario Del Piano; Giovanni Mogna
Journal:  J Clin Gastroenterol       Date:  2014 Nov-Dec       Impact factor: 3.062

3.  Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats.

Authors:  I R Rowland; C J Rumney; J T Coutts; L C Lievense
Journal:  Carcinogenesis       Date:  1998-02       Impact factor: 4.944

4.  Plasma enterolactone or intestinal Bifidobacterium levels do not explain adenoma formation in multiple intestinal neoplasia (Min) mice fed with two different types of rye-bran fractions.

Authors:  S Oikarinen; S Heinonen; S Karppinen; J Mättö; H Adlercreutz; K Poutanen; M Mutanen
Journal:  Br J Nutr       Date:  2003-07       Impact factor: 3.718

5.  A new morphologically characterized cell wall preparation (whole peptidoglycan) from Bifidobacterium infantis with a higher efficacy on the regression of an established tumor in mice.

Authors:  K Sekine; T Toida; M Saito; M Kuboyama; T Kawashima; Y Hashimoto
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

6.  Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy.

Authors:  Ayumi Hidaka; Yoshinori Hamaji; Takayuki Sasaki; Shun'ichiro Taniguchi; Minoru Fujimori
Journal:  Biosci Biotechnol Biochem       Date:  2007-12       Impact factor: 2.043

7.  Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis).

Authors:  Jordane Biarc; Isabelle S Nguyen; Annelise Pini; Francine Gossé; Sophie Richert; Danielle Thiersé; Alain Van Dorsselaer; Emmanuelle Leize-Wagner; Francis Raul; Jean-Paul Klein; Marie Schöller-Guinard
Journal:  Carcinogenesis       Date:  2004-01-23       Impact factor: 4.944

8.  Cross-feeding by Bifidobacterium breve UCC2003 during co-cultivation with Bifidobacterium bifidum PRL2010 in a mucin-based medium.

Authors:  Muireann Egan; Mary O'Connell Motherway; Michelle Kilcoyne; Marian Kane; Lokesh Joshi; Marco Ventura; Douwe van Sinderen
Journal:  BMC Microbiol       Date:  2014-11-25       Impact factor: 3.605

9.  Bifidobacteria or Fiber Protects against Diet-Induced Microbiota-Mediated Colonic Mucus Deterioration.

Authors:  Bjoern O Schroeder; George M H Birchenough; Marcus Ståhlman; Liisa Arike; Malin E V Johansson; Gunnar C Hansson; Fredrik Bäckhed
Journal:  Cell Host Microbe       Date:  2017-12-21       Impact factor: 31.316

10.  Non Digestible Oligosaccharides Modulate the Gut Microbiota to Control the Development of Leukemia and Associated Cachexia in Mice.

Authors:  Laure B Bindels; Audrey M Neyrinck; Nuria Salazar; Bernard Taminiau; Céline Druart; Giulio G Muccioli; Emmanuelle François; Christophe Blecker; Aurore Richel; Georges Daube; Jacques Mahillon; Clara G de los Reyes-Gavilán; Patrice D Cani; Nathalie M Delzenne
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

View more
  11 in total

1.  Gut microbiome and neurosurgery: Implications for treatment.

Authors:  Jonathan Willman; Matthew Willman; Ramya Reddy; Anna Fusco; Sai Sriram; Yusuf Mehkri; Jude Charles; Joel Goeckeritz; Brandon Lucke-Wold
Journal:  Clin Transl Discov       Date:  2022-10-10

2.  Alterations in co-abundant bacteriome in colorectal cancer and its persistence after surgery: a pilot study.

Authors:  Chin-Wen Png; Yong-Kang Chua; Jia-Hao Law; Yongliang Zhang; Ker-Kan Tan
Journal:  Sci Rep       Date:  2022-06-14       Impact factor: 4.996

3.  Shifts in Bacterial Diversity During the Spontaneous Fermentation of Maize Meal as Revealed by Targeted Amplicon Sequencing.

Authors:  Grace Nkechinyere Ijoma; Ramganesh Selvarajan; Tracy Muntete; Henry Joseph Oduor Ogola; Memory Tekere; Tonderayi Matambo
Journal:  Curr Microbiol       Date:  2021-02-23       Impact factor: 2.188

4.  Aging, Frailty, and the Microbiome-How Dysbiosis Influences Human Aging and Disease.

Authors:  John P Haran; Beth A McCormick
Journal:  Gastroenterology       Date:  2020-12-08       Impact factor: 22.682

Review 5.  Colorectal Cancer and Probiotics: Are Bugs Really Drugs?

Authors:  Purushottam Lamichhane; Morgan Maiolini; Omar Alnafoosi; Sedra Hussein; Hasan Alnafoosi; Stewart Umbela; Tayanna Richardson; Nevien Alla; Narottam Lamichhane; Bobban Subhadra; Rahul R Deshmukh
Journal:  Cancers (Basel)       Date:  2020-05-05       Impact factor: 6.639

6.  Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer.

Authors:  Ming-Feng Hou; Fu Ou-Yang; Chung-Liang Li; Fang-Ming Chen; Chieh-Han Chuang; Jung-Yu Kan; Cheng-Che Wu; Shen-Liang Shih; Jun-Ping Shiau; Li-Chun Kao; Chieh-Ni Kao; Yi-Chen Lee; Sin-Hua Moi; Yao-Tsung Yeh; Chien-Ju Cheng; Chih-Po Chiang
Journal:  Exp Mol Med       Date:  2021-10-27       Impact factor: 8.718

Review 7.  The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development.

Authors:  Claire M Doocey; Karen Finn; Craig Murphy; Caitriona M Guinane
Journal:  BMC Microbiol       Date:  2022-02-12       Impact factor: 3.605

Review 8.  Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence.

Authors:  Aurora Mirabile; Licia Rivoltini; Elena Daveri; Claudio Vernieri; Roberto Mele; Luca Porcu; Chiara Lazzari; Alessandra Bulotta; Maria Grazia Viganò; Stefano Cascinu; Vanesa Gregorc
Journal:  Cancers (Basel)       Date:  2020-05-04       Impact factor: 6.639

Review 9.  Microbiota and cancer: current understanding and mechanistic implications.

Authors:  A A Khan; A T Sirsat; H Singh; P Cash
Journal:  Clin Transl Oncol       Date:  2021-08-13       Impact factor: 3.405

Review 10.  Early-onset colorectal cancer: Current insights and future directions.

Authors:  Claudia Wing-Kwan Wu; Rashid N Lui
Journal:  World J Gastrointest Oncol       Date:  2022-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.